

**INDIAN INSTITUTE OF TECHNOLOGY ROORKEE**

**NPTEL**

**NPTEL ONLINE CERTIFICATION COURSE**

**Biomedical Nanotechnology**

**Lec-17**

**Nanopharmacology & Drug Targeting**


**Dr. P. Gopinath**

**Department of Biotechnology**

**Indian Institute of Technology Roorkee**

Hello everyone I welcome all to these 17<sup>th</sup> lecture of this course the 17<sup>th</sup> lecture is on nano pharmacology and drug targeting, so in this lecture we are going to learn what is nano pharmacology.

(Refer Slide Time: 00:30)



And various nano pharmacology targets and also how to target the drug to a particular organ.

(Refer Slide Time: 00:37)

## Nanopharmacology

- Nanopharmacology, a new branch of pharmacology is gradually emerging with the application of nanoscience and nanotechnology in the field of nanomedicine.
- Drug design and drug delivery to selected targets to improve pharmacodynamics and kinetic profiles toward safer and effective treatment is known as nanopharmacology.
- Pharmacokinetics may be simply defined as what the body does to the drug, as opposed to pharmacodynamics which may be defined as what the drug does to the body



ST. XAVIER'S

MPH, ONLINE  
CERTIFICATION COURSE

So this nano pharmacology is a new branch of pharmacology and its gradually emerging with the application of nano science and nanotechnology, so let us see the definition of nano pharmacology so it is a drug design and drug delivery to select a targets to improve the pharmacodynamics and kinetic profiles towards safer and effective treatment okay, and let us see the definition between the pharmacokinetics and pharmacodynamics so the pharmacokinetics is simply defined as what the body does to the drug.

Okay, and the pharmacodynamics is what the drug does to the body okay, so based on the pharmacokinetics and pharmacodynamics the efficiency of drug get varied.

(Refer Slide Time: 01:21)

## Categorized nanopharmacology


- Defining targets
- Development of drugs and carrier systems
- Studying target–drug interactions
- Monitoring the target–drug interaction outcomes



So let us see how the nano pharmacology can be categorized the first one is differing the targets and next one is development of drugs and carrier system and the third one is studying the target drug interaction and fourth one is monitoring the target drug interaction outcomes, so let us see these in detail one by one.


(Refer Slide Time: 01:36)

## Defining targets



The first one is depending the targets so when you make a drug we should exactly match with the your binding side that is your receptor side, so which is not binding effectively then the therapeutic efficiency will be less. For example so if your receptor is like this.


(Refer Slide Time: 01:54)



So the drug should go an exactly match with this okay and this is your receptor or a binding side, and if your drug is like this it cannot bind with the binding side so that efficiency will be less if the target is not matching with the drug.

(Refer Slide Time: 02:16)

## Development of drugs and carrier systems



So the next one is development of drugs and carrier systems so we can make a biocompatible and biodegradable and nano carriers which can deliver the drug to the targeted location, for example we can use that human serum albumin so this actual say it is one of the highly biocompatible and biodegradable material okay, and we can load with the any can have drug and also we can target these HAS to the particular location for example if the target is nano particle to the cancer.

We can have the cancers specific antibodies so that it can go and bind only to the cancer cell and it can release the antibodies drug to the cancer cells.

(Refer Slide Time: 02:56)

## Studying target–drug interactions

- Pharmacokinetic interactions
  - Absorption
  - Distribution
  - Biotransformation
  - Excretion
- Pharmacodynamic interactions
  - Receptor interaction
  - Receptor sensitivity
  - Drug transportation



Dr. ROSEBERRY

NPTEL ONLINE  
CERTIFICATION COURSE

7

So next one is the studying the target drug interaction, so in case will be learning pharmacokinetic interactions as well as pharmacokinetic interactions as well as pharmacodynamics interactions, so under the pharmacokinetic interaction will be studying the how the drug will be absorbed and what is the distribution and also the biotransformation excretion of the particular drug, and in the pharmacodynamic interactions will be studying how the drug will be interacting.

With the receptor and how if the sensitivity whether it is binding only to the cancer cells or it is binding to the number cell also so those case can be studied and how the drug is transported so these things come under the pharmacodynamic interactions.

(Refer Slide Time: 03:31)

## Studying target–drug interactions



- Usually, the binding sites of macromolecules are more hydrophobic in nature than the surface, and so this enhances the effect of an ionic interaction.
- The drop off in ionic bonding strength with separation is less than in other intermolecular interactions, so if an ionic interaction is possible, it is likely to be the most important initial interaction as the drug enters the binding site.



And another important thing is studying the target drug interaction usually the binding site of macromolecules are more hydrophobic in nature okay, so this enhances the effects of an ionic interaction for example if you are having that target with the positive charge and it will be nice if you are have a drug with negative charge it can easily go and bind based on the ionic or electrostatic interactions, and as we know that most of a cells and nucleic acid these have neutrally charge okay.


So when you have the drug with the positive charge it can easily go and bind to the electrostatic interaction, so if an ionic interaction is possible it is likely to be most important initial interaction as a drug enters the binding site.

(Refer Slide Time: 04:15)




## Example

- Both cationic and anionic particles penetrate and accumulate in tumors.
- However, only cationic particles diffuse fully throughout the tumor.



So for example we can see here this cationic and anionic nano particles can penetrate and accumulate in tumors but this cationic particles diffuse fully throughout the tumor, so we can see here so this anionic particles and this is the cationic particles and in the cationic particles it is a fully diffused throughout the tumor and whereas anionic particle it is not diffused properly and compared to the cationic particles.

(Refer Slide Time: 04:39)



So next important thing is quantitative systems pharmacology so that is QSP so in this will studying the systematic as well as holistic understanding of the drug action, and this is a divided into two categories like vertical integration and horizontal integration okay so here when we make a new drug will be purifying the compounds with the help of chemistry and will be telling the effect of this purified compounds on the cells and then you will study the effect of this drug on the organs.

Then you study these effect of this drug on the animals and patients and then the populations so here in vertical impression we will be studying the interaction of drug with these group okay and in the horizontal integration so you will studying the interaction of drug with the target and how the it will interacting with the cellular networks and also what is the molecular mechanism of the particular drug, so everything will be studying under the horizontal integration.

(Refer Slide Time: 05:35)

## Monitoring the target–drug interaction outcomes

- 1) Loss of therapeutic effect
- 2) Toxicity
- 3) Unexpected increase in pharmacological activity
- 4) Beneficial effects e.g additive & potentiating (intended) or antagonism (unintended).
- 5) Chemical or physical interaction  
e.g I.V incompatibility in fluid or syringes mixture




And next one is the monitoring the target drug interaction outcomes okay, so when you give the drug we have to check whether there is any loss of therapeutic effect and what is the toxicity of the particular drug and whether any unexpected increasing the pharmacology activity and for example it may give some beneficial effects for example it can give addictive or sometime it may give antagonism effect and next thing is we have to study the chemical as well as physical interaction for example you have to study whether your drug is compatibility in fluid or syringes mixture.

(Refer Slide Time: 06:10)

## Conventional therapy

In the conventional therapy aliquot quantities of drugs are introduced into the system at specified intervals of time with the result that there is considerable fluctuation in drug concentration level as indicated in the figure.




So let us see what is the drawback of conventional therapy so in the conventional therapy so we will be using the particular conventional of drug and that particular concept drug will be taken at specified intervals of time, so due to which what will happen there will be a fluctuation in the drug concentration level we can see here, so the concentration of drug is going high and low.

(Refer Slide Time: 06:33)

## Ideal dosage regimen

However, an ideal dosage regimen would be one, in which the concentration of the drug, nearly coinciding with **minimum effective concentration (M.E.C.)**, is maintained at a **constant level** throughout the treatment period. Such a situation can be graphically represented by the following figure



So for an ideal dosage enough to take the concentration which is nearly matching with the minimum effective concentration that is MEC okay and it should be maintain in a constant level throughout the treatment period, so then only the therapeutic efficiency of the drug can be increased.

(Refer Slide Time: 06:48)

## Nanopharmacology target

- Slow release nanopharmacology
- Controlled release nanopharmacology
- Bio barrier penetration nanopharmacology




So let us see the various nano pharmacology targets so under this we will be studying about what is slow release nanopharmacology and what is control is nana pharmacology and also will be studying about the bio barrier penetration nanopharmacology.

(Refer Slide Time: 07:05)

## Slow release nanopharmacology

The slow release nanopharmacology studies the question on how to realize the slow release and the influences of slow release on the drug metabolisms and the therapeutic effects.



So first we will see what is slow release nanopharmacology so here the slow release nanopharmacology studies the question on how to realize the slow release and influence of slow release under drug metabolism and therapeutic effects, so we can see here there is a non stabilized carrier so where the drug is releasing very rapidly so when the drug is released in more concentration what all happen is like a it will removed by your reticular endo theory system so it will be removed by the liver as well as spleen.

And in case of stabilized carrier you drug will be released very slowly okay and we can see here it can slowly release the drug and it can stain the blood stream for more time.

(Refer Slide Time: 07:53)

## What is sustain release dosage form?

Drug Delivery system that are designed to achieve *prolonged therapeutic effect* by continuously releasing medication *over an extended period of time* after administration of single dose.

The *basic goal* of therapy is to *achieve steady state blood level* that is therapeutically *effective* and *non toxic* for an extended period of time.

The design of proper dosage regimen is an important element in accomplishing this goal.



So before we study the control is nanopharmacology let us see what is sustain release dosage form okay so here that drug delivery system that are design to achieve prolonged therapeutic effect by continuously releasing the drug or an extended period of time okay after administration of single dose and the basic goal of the therapy is to achieve steady state blood level that is therapeutically effective, and non toxic for an extended period of time, so the design of proper dosage regimen is an important element in achieving this goal.

(Refer Slide Time: 08:27)



## The difference between controlled release and sustained release



**Controlled drug delivery-** which delivers the drug at a *pre determined rate* for a specified period of time

**Controlled release** is perfectly zero order release that is the drug release over time irrespective of concentration.

**Sustain release dosage form-** is defined as the type of dosage form in which a *portion i.e. (initial dose)* of the drug is **released immediately**, in order to achieve desired therapeutic response more promptly, and the *remaining(maintanance dose)* is then **released slowly** there by achieving a therapeutic level which is prolonged, but not maintained constant.

**Sustained release** implies slow release of the drug over a time period. *It may or may not be controlled release.*

4



17


So let us see the different between the control release and sustain release so the control delivery is then which deliver the drug at a pre determine rate for a specified period of time that is called as control drug delivery, and here the control release is perfectly 0 order release okay that means the drug release over time it is irrespective of concentration, and in case of sustain release it is different as type of dosage form in which a portion of the drug that is initial dose of drug will be released immediately.

And in order to achieve the desired therapeutically response more promptly okay, so initially the drug will be released immediately to achieve the desired therapy effect more promptly and then the remaining drug that is maintain those that will be released slowly and there be achieving at therapeutic level which is prolong and but not maintain constant level okay, so this sustain implies slow release of drug over a period of time and it may or may not be controlled release.

(Refer Slide Time: 09:30)

## Controlled release nanopharmacology

The controlled-release nanopharmacology studies how to realize the smart release of the drugs according to the therapeutic needs in the cellular and tissue microenvironments.



P. ROOPER



NPL ONLINE CERTIFICATION COURSE


18

So let us see the control release nanopharmacology so here the controlled release nanopharmacology studies how to realize this smart release of the drugs according to the therapeutic needs in the cellular and tissue microenvironments so can use a smart nano carrier for example we can make a smart nano carrier which can release the insulin depends on the blood glucose level if there is a more blood glucose level it can release the insulin from the smart nano carrier system.

(Refer Slide Time: 10:00)

## Bio barrier penetration nanopharmacology

- Bio-barrier-penetration nanopharmacology studies the capabilities of nanodrugs to passing through bio-barriers.
- Blood-brain barrier
- Air-blood barrier
- To realize the treatment of some focal diseases where the traditional drugs can't arrive because their incapability to penetrate biobarriers.



So the next one is bio barrier penetration nanopharmacology, so here the bio barrier penetration nanopharmacology studies the capabilities of nanodrugs to passing through the bio barriers, so the two important bio barriers is blood brain barrier and other one is air blood barrier, okay so to realize the treatment of some diseases where the traditional drugs cannot reach because of the incapability to penetrate these bio barriers.

So we can use the nano carriers which can easily cross the blood brain barrier and it can deliver the drug and which could be useful for various therapeutic applications.

(Refer Slide Time: 10:39)

## What really happens when you take a drug?

Patient group

Same diagnosis, same prescription

- Can we predict drug efficacy and toxicity?
- Can we reuse old drugs?
- Can we design personalized medicines?

EPICURE
 MPLCMMR  
 DRUG RESEARCH CENTRE

So let us see what really happens when you take a drug, so this is a patient group and same diagnosis and same prescription but you can see here different kind of effects, so to particular group the drug may be toxic but it is beneficial to other group the drug is toxic and not beneficial and to the other group the drug is not toxic and not beneficial and to other group it will be not toxic and beneficial.

So where to study the effect of the drug to different patient groups before we take it for commercial application, so here the question is can we predict the drug efficacy and toxicity and can we reuse the old drugs or can we design the personalized medicine for the particular patients need.

(Refer Slide Time: 11:26)

## The perfect drug!

### Reality

- All drugs have side effects but new drugs aim to provide beneficial effects with minimal side effects

### How is this achieved?

1. Identify new molecules
  2. Modify structure of known molecules
- Test in biological tissue or whole body



13 DEC 2018



21

So what is the perfect drug okay, so here the all drugs have side effects but new drugs aim to provide beneficial effects with the minimal side effects okay, so it can be achieved so by identifying a new molecules or modifying the structure of the known molecules and testing these in the biological tissue or the whole body.

(Refer Slide Time: 11:47)

## ADME evaluation and drug design

### ADME:

an abbreviation in pharmacokinetics and pharmacology for "absorption, distribution, metabolism, and excretion," and describes the disposition of a pharmaceutical compound within an organism.

The four criteria all influence the drug levels and kinetics of drug exposure to the tissues and hence influence the performance and pharmacological of the compound as a drug.


So if you make any drug, so first thing we have to do the ADME evaluation okay, so based on that we have to design the drug. So what is ADME evaluation so ADME means so it is a abbreviation in pharmacokinetics and pharmacology for absorption, distribution, metabolism and excretion so how the drug will be observed, how it is distributed in the body and what is the metabolism and how it will be excreted from the body, okay.

And this four criteria influence the drug levels and kinetics of drug exposure to the tissues and thus it influence the performance and pharmacological of the compound as a drug.

(Refer Slide Time: 12:23)

## Multiorgan microdevices for ADME evaluation and drug design

- Multiorgan micro-devices are in-vitro set up of animal cells to simulate the same physiological environment and study the effect of drug on different cells and organs.



- These systems are capable of simulating human metabolism.

<https://thereslack.io/organs-on-chips-emulates-human-organs-for-better-biomedical-testing/>



For ADME evaluation we can use the multiorgan microdevice instead of using the animal model okay, so we can use this multiorgan microdevice so this multiorgan microdevice are the in vitro set up of animal cells to stimulate the same physiological environment and study the effect of drug or different cells and organs. So here these system are capable of stimulating the human metabolism.

So this is like a organ on a chip or human on a chip so this chip will mimic like your human metabolism, so we can add that drug into this chip and we can study the effect of the drug on the particular organ.



(Refer Slide Time: 12:59)

## Human-on-a-Chip

- The devices have the potential to predict potential toxic side effects with higher accuracy before a drug enters the expensive and time consuming phase of clinical trials.
- Since single organ devices are testing platforms for tissues that can later be combined with other tissues within multi-organ devices
- Multi-organ micro-devices can be seen as physical representations of **Physiologically based pharmacokinetic models** in which the organs are represented by an actual compartment.
- Devices could be a way for the development of individualized medicine.

*Human-on-a-Chip*

<https://thenewslack.io/organs-on-chips-emulates-human-organs-for-better-biomedical-testing/>



24

So you see here this example of human on a chip, so we can make this kind of chip we will study how the drug will be excreted okay, so this is like a kidney on a chip and next to one is we can also make a gut okay, so and we can study how the drug will be observed and also we can the liver on the chip and we can study the metabolism of drugs and we can make a bone marrow on the chip and that will tell you the what can a remainder spots it will the drug will induce, okay.

So here the devices have the potential to predict the potential toxics side effects with higher accuracy before a drug enters the expensive and time consuming phase of clinical trials. So before we take the drug to the clinical trial which is time consuming and expensive so we can use this lab on a chip or human on a chip and we can study the effective of this drug on this then we can take it for that for the clinical trial and commercial applications.

So since the single organ device are testing platforms for tissues so that can be later be combined with other tissues within multi organ devices and here the multiorgan micro devices can be seen as the physical representation of physiologically based pharmacokinetic models in which the organs are represent by an actual compartment, okay. So and this devices could be a wave for the development of individualized or personalized medicine.

(Refer Slide Time: 14:21)



## Drugs dispersion

- Live saving drugs are one of the important ingredients in the latest medicines but its unusual and excess usage could cause death.
- Nanomedicine also has successful applications for the reduction of extra drugs from human body.
- Implantation of nanomedicine devices could disperse drugs or hormones as required in people with chronic imbalance or deficiency states.


So let us see the drug dispersion, so here the live saving drugs are one of the important ingredients in the latest medicines but it is unusual and excess usage could cause death. So the nanomedicine has a successful applications for the reduction of extra drugs from the human body and implantation of nanomedicine and devices could disperse drugs or hormones as required in people with chronic imbalance or deficiency states.

So this nanomedicine or nano carrier it can act like a small dilute system and according to the need of the patient it can release the drug and it can save the person from the particular disease.


(Refer Slide Time: 15:01)

## Entrapment or Encapsulation

- **Encapsulation** involves surrounding drug molecules with a solid polymer shell



- **Entrapment** involves the suspension of drug molecules within a polymer matrix.




So let us see the difference between entrapment and encapsulation of drug so encapsulation of drug means it involves a surrounding the drug molecules with a solid polymer shell okay, so this yellow color is your drug and it is surrounded by a polymer and entrapment means it involves the suspension of drug molecules within a polymer matrix, you can see this yellow is a drug and this blue color is a polymer. So the drug is entrapped between the polymer matrix.

(Refer Slide Time: 15:29)

## Drug release by diffusion

- When the polymer absorbs water it swells in size.
- Swelling created voids throughout the interior polymer.
- Smaller molecule drugs can escape via the voids at a known rate controlled by molecular diffusion (a function of temperature and drug size).



So let us see that drug release by the diffusion so when the polymer absorbs water it swells in size okay, and this swell in created avoids throughout the interior polymer and the smaller molecules can escape through the voids at a known rate controlled by molecular diffusion okay. So when you put this nano particle into water so it will swell and it will release the drug slowly, and we can control the release of this drug by simple cross linking reaction.

So based on the cross linking, so we can control the release of the drug, we can he want more release of drug at initial stage we can do it or he want to release the drug slowly that also can be possible.


(Refer Slide Time: 16:08)

## Major areas of development of nanomedicine

- Prevention and control
- Early detection
- Imaging diagnostics
- Multifunctional Therapeutics

And the major areas of development of nanomedicine is prevention and control and by using this nano materials we can early detect any disease and also we can use it for very diagnostic application and also we can make a multi function nano materials which can do the diagnostics as well as therapeutics simultaneously.

(Refer Slide Time: 16:27)




So let us see these summary of check points for nanomedicine design and optimization okay, so before we take this nanomedicine for clinical application we have to cross all these steps. So first thing is we have to study the safety of nano material in, in vitro, in vivo and we will be studying the bio distribution in, in vitro and in vivo and we have to make sure that what is that drug and imaging agent carrying capacity, it can be theoretical or it can be in vitro studies.

And you will be studying the drug release rate in vitro and we will be studying the effect of this drug on the cells then you will study the effect of this drug on the animal model and human applications in a particular group okay, so then you will be taking it for commercial applications. So each and every drug has to cross through all those steps okay, so then only it can reach the market for commercial application. So that is why each and every drug it is taking at least 10 to 15 years to reach the market.

(Refer Slide Time: 17:23)

## Nano Impact in medicine

- Nanotechnology holds key to a number of recent and future breakthroughs in medicine




So let us see the impact of nano in the medicines okay, so let us see the comparison between the current strategies as well as nano strategies, so if you want to screen a particular disease by using the current methodology there may be a chance for non physics markers and when we use the nano material we can go and buy only to the specific markers and here we can do limited number of test but here we can do the large number of test using this lab on a chip and in case of diagnosis like macro scale site imaging by using the current methodology.

But here we can use the whole body as well as it can be non immersive, in current strategy we have to go for immersive technology okay, and here in case of treatment we have to go for surgery or radiation okay, and whole body pharmacokinetics and here we can reduce that surgery it can be minimal immersive or we can make a drug which can be derived to the particular target okay, so the target delivery is possible.

And again for follow up we have to use the macro scale site imaging and here then when you use the nano we can use the non immersive qualitative imaging and we can also do the early diagnosis under early follow up.

(Refer Slide Time: 18:32)



So let us see how we can target this drug to a particular organs.

(Refer Slide Time: 18:37)

## Contents

- Drug Delivery to respiratory system.
- Problems of drug delivery to the brain and targeting to brain.
- Drug delivery to eye.
- Drug targeting in neoplastic diseases.



So under this we are going to see how we are going to target this drug to the respiratory system and how we can target the drug to the brain and how we can target drug to the eye as well as the neoplastic diseases.

(Refer Slide Time: 18:48)



## Targeting all respiratory system

- Dosing to the complete respiratory system has previously only been possible by special nebulizer.
- Dosing to the complete respiratory system has only been regarded as an option for a very narrow range of therapeutics.

So let us see how we can target the drug to the respiratory system the dosing to the complete respiratory system was possible previously by a specialized nebulizer and dosing to the complete respiratory system has only been regarded as option for a very few narrow range of therapeutics, so some of the disease we have to deliver the drug to the respiratory system directly, okay. So in those cases we can make a inhalable nano particles or micro particles so that can reach their respiratory system and it can deliver the drug.

(Refer Slide Time: 19:19)

## Gas composition

- The particle-loaded inhaled gas is **heavier** (lighter) than air, particles **penetrate deeper** (less deep) into the lungs.
- Deposition occurs deeper in the lungs when particle-loaded sulphox rather than particle loaded heliox is inhaled.

So here the particle loaded inhaled gas is if it is heavier it can penetrate deeper in the lungs and if it is lighter it can penetrate less deep okay, for example the deposition occurs deeper in the lungs when particle loaded with sulphox drug okay, when compared to the heliox drug.

(Refer Slide Time: 19:38)

## Emerging carriers for respiratory drug delivery


- Nanoparticle Formulations for Inhalation
- Vaccine delivery
- Gene therapy



So we can make this nano particle formulations for vaccine delivery and gene therapy and also for various other drug delivery applications, so we can make the inhalable nano particles.

(Refer Slide Time: 19:49)


## Targeted delivery to the respiratory system



So let us see how we can deliver the drug to the respiratory system so using the nebulizer we can deliver this inhalable nano particles to the person and this can reach the lungs and it can deliver the drugs.

(Refer Slide Time: 20:01)

## Liposomes as drug delivery systems to alveolar macrophage



For example it can be used for the lung cancer or other lung related diseases, so we can use for micro bacterium tuberculosis therapy. So you can have the little based carriers or polymeric nano carriers, which can reach the lungs and kill the micro bacterium tuberculosis.

(Refer Slide Time: 20:22)

## Protein and peptide drugs to the respiratory system

- Decreasing irritation caused by the drug
- Decreasing toxicity due to high initial doses of the drug
- Altering the immunogenicity of the protein
- Improving taste of the product
- Improving shelf life of the product

And we can also have the protein and peptide based drugs to the respiratory system, so that is the decrease the irritation cause with the drug and also it will decrease the toxic to high initial doses of the drug and also it will alter the immunogenicity of protein and also improve the taste of the product and also it will improve the shelf life of the product.

(Refer Slide Time: 20:40)

---

## Drug delivery to brain

---

So let us see how can we deliver the drug to the brain.

(Refer Slide Time: 20:44)

## Problems of Drug Delivery to the Brain


- The relative impermeability of the BBB results from tight junctions between capillary endothelial cells which are formed by cell adhesion molecules.
- Approximately 98% of the small molecules and nearly all large molecules, such as recombinant proteins or gene-based medicines do not cross the BBB.

So the problems of drug delivery to the brain is like, the relative impermeability of the blood brain barrier, due to the tight junctions in the capillary endothelial cells which are formed by the cell adhesion molecules and approximately 98% of the small molecules and nearly all large molecules, such as recombinant proteins or gene based medicines do not cross the blood brain barrier. So that is the major problem for delivering drug to the brain, so most of the drugs it cannot cause the blood brain barrier.

(Refer Slide Time: 21:16)




# Blood Brain Barrier (BBB)



Endothelial cell  
Capillary

Endothelial Cell  
National Medicine Research, UK, 1991



Blood Brain Barrier  
National Medicine Research, UK, 1991

BBB is formed by a network of **endothelial cells** and is impermeable to large molecular weight chemotherapeutic agents (large proteins).

**CNS Disorders Requiring LARGE Molecules Drug Therapy**

- ❖ Alzheimer's Disease
- ❖ Parkinson's Disease
- ❖ Huntington's Disease
- ❖ Autism
- ❖ Multiple Sclerosis
- ❖ Brain Cancer
- ❖ Stroke
- ❖ Brain Trauma
- ❖ Lysosomal Storage Disorders
- ❖ Inherited Ataxias

**CNS Disorders Treatable With small Drug Molecules**

- ❖ Depression
- ❖ Schizophrenia
- ❖ Chronic Pain
- ❖ Epilepsy

Ref: William M. Partridge, 2005

So this blood brain barrier is formed by the network of endothelial cells as I told you earlier and it is impermeable to large molecular weight chemotherapeutic agents. So what are the diseases that we have to send the drugs to the brains? For example CNS disorders requiring the large molecules drug therapy is, Alzheimer disease, Parkinson disease oaky, and other disorders which need which need small drug molecules like depression, schizophrenia, chronic pain, so these things need a small drugs molecule.

(Refer Slide Time: 21:46)

## Drug targeting to brain

To bypass the BBB and to deliver therapeutics into the brain, three different approaches are currently used.


1. Invasive approach
2. Pharmacological approach
3. Physiological approach



So let us see how we can target the drug to the brain, to bypass the blood brain barrier therapeutics into the brain, three different approaches are currently used, first one is invasive approach, the next one is pharmacological approach and the physiological approach.

(Refer Slide Time: 22:01)

## Drug targeting in the brain areas



First one is invasive approach; we have to inject the drug directly to the brain.

(Refer Slide Time: 22:09)

## Pharmacological approach

- Pharmacological approach consists of modifying, through medicinal chemistry, a molecule that is known to be active against a CNS target to enable it to penetrate the BBB.
- Modification of drugs through a reduction in the relative number of polar groups increases the transfer of a drug across the BBB.
- Lipid carriers have been used for transport.



So let us see the pharmacological approach is consists of modifying through medicinal chemistry, a molecule that is known to be active against a CNS target to enable it to penetrate the blood brain barrier and here the next one is modification of drugs through a reduction in the relative number of polar groups increase the transfer of a drug across the blood brain barrier. So here the mostly the liquid carriers have been used for the transport to the blood brain barrier.

(Refer Slide Time: 22:36)

## Pharmacological approach

- Formulation of drugs facilitates brain delivery by increasing the drug solubility and stability in plasma
- Limitations: The modifications necessary to cross the BBB often result in loss of the desired CNS activity. Increasing the lipophilicity of a molecule to improve transport can also result in making it a substrate for the efflux pump P-glycoprotein (P-gp).



So here in the pharmacological approach like formulation of drugs which facilitates brain delivery by increasing the drug solubility and stability in plasma but the limitations are the modifications necessary to cross the blood brain barrier often result in loss of the desired CNS activity and increasing the lipophilicity of a molecule to improve transport can also result in making it a substrate for the efflux pump P glycoprotein. Okay so when you modify the drugs, causing the blood brain barrier, what happens is? It may lose its therapy activities or it may be removed by the P glycoprotein form.

(Refer Slide Time: 23:13)

## Physiological approach


Physiological approach is recognized by the scientific community as the one with the most likely chance of success.

- Transporter-mediated delivery
- Receptor-mediated transcytosis
- Receptors at the blood–brain barrier



So let us see the pharmacological approach, pharmacological approach is recognized by the scientific community as the one with the most likely chance of success, so here the drug will be delivered to the brain region by transported mediated delivery, and receptor mediated transcytosis and the receptors at the blood brain barrier.


(Refer Slide Time: 23:31)



So you can see here hydrophilic molecules can cross the blood brain barrier using this transporter or specific carrier endocytosis or it can be the para cellular pathway and the lipophilic molecules can simply diffuse the blood brain barrier.

(Refer Slide Time: 23:56)

## MRI photoacoustic–Raman (MPR) imaging technique to delineate the tumor




Let us see an example how these nanoparticles can be used for imaging the brain tumor, so this is the MRI photoacoustic Raman imaging technique to delineate the tumor. So these nanoparticles are injected into a mouse bearing an orthotopic brain tumor and these nanoparticles can circulate in the blood stream and it diffuses to the disrupted blood brain barrier and that will be retained by the tumor and this MPR is too large to cross the intact blood brain barrier, so it cannot be accumulated in healthy brain.

And you can see here these MPR is made of gold core and the Raman active layer and followed by you are having this silica shells and top you are having the gold that is coating. So by using these nanoparticles the imaging of brains can be done in three levels like, pre surgery MRI, surgery and also post surgery also.

(Refer Slide Time: 24:57)





So let us see how we can deliver the drug to the eye.

(Refer Slide Time: 25:00)

## Drug delivery to eye

- Ophthalmic preparation
  - Applied topically to the cornea, or instilled in the space between the eyeball and lower eyelid
- Solution
  - Dilutes with tear and wash away through lachrymal apparatus
  - Administer at frequent intervals



So in the ophthalmic preparation, it can be applied topically to the cornea, or instilled in the space between the eyeball and lower eyelid okay, so we can use the solution, but the problem is dilutes with tear and wash away through lachrymal apparatus and we can also administer at frequent intervals.

(Refer Slide Time: 25:20)

## Drug delivery to eye

- Suspension
  - Longer contact time
  - Irritation potential due to the particle size of drug
- Ointment
  - Longer contact time and greater storage stability
  - Producing film over the eye and blurring vision



And we can use the suspensions it will longer contact time and it may cause irritation due to the particle size of the drug ad in the ointment and again in the longer contact time and grater storage stability and it may produce the film over the eye and blurring vision.

(Refer Slide Time: 25:38)

## Drug delivery to eye

- Emulsions
  - Prolonged release of drug from vehicle but blurred vision, patient non compliance and oil entrapment are the drawbacks.
- Gels
  - Comfortable, less blurred vision but the drawbacks are matted eyelids and no rate control on diffusion.



And we can use the emulsion for the better view here it can have the prolonged release of drug from the vehicle but blurred vision, patient non compliance and oil entrapment are the drawbacks and we can also use the gels it is comfortable less blurred vision but the drawbacks are matted eyelids and no rate control on diffusion.

(Refer Slide Time: 26:02)

## Drug delivery to eye

- **Controlled delivery system**
  - Release at a constant rate for a long time
  - Enhanced corneal absorption
  - Drug with not serious side effect or tolerate by the patient

So we can have the nano carriers which will have the controlled system, so it will release at a constant rate for a long time, enhanced corneal absorption and also the drug with not serious side effect or it can be tolerated by the patient.

(Refer Slide Time: 26:17)

## Advantages

- Increase ocular residence, hence, improving bioavailability.
- Possibility of providing a prolonged drug release and thus a better efficacy.
- Lower incidence of visual and systemic side effects.
- Increased shelf life with respect to aqueous solutions.
- Exclusion of preservatives, thus reducing the risk of sensitivity reactions.

So here the advantages are increase ocular residence hence improving bio availability and it will increase the possibility o providing a prolonged drug release and thus a better efficacy, and also the lower incidence of visual and systemic side effects and increase shelf life with respect to aqueous solutions and exclusion of preservatives thus reducing the risk of sensitivity reactions.


(Refer Slide Time: 26:45)

## Advantages

- Possibility of targeting internal ocular tissue through non-corneal routes
- Reduction of systemic side effects and thus reduced adverse effects.
- Reduction of the number of administration and thus better patient compliance.
- Administration of an accurate dose in the eye, which is fully retained at the administration site, thus a better therapy.

So other advantages are it will reduce the systemic side effects and thus reduced adverse effects and you can reduce the number of administration and thus better patient compliance and also the administration an accurate dose in the eye, which is fully retained at the administration site so that will improve the therapeutically efficiency.

(Refer Slide Time: 27:06)




So we can deliver the drug to the eye using there are various carriers we can use the liposome okay we can also use the micro particles, nano particles, so depend on the drugs as well as depends on the diseases, sop according to the target we have choose the suitable carrier.

(Refer Slide Time: 27:23)



## Nanomedicine for the eye.....

**Sustained-release Liposomal Carrier**



The diagram illustrates the application of a liposomal carrier in an eye with glaucoma. On the left, a cross-section of a liposomal carrier is shown, labeled 'Sustained-release Liposomal Carrier'. It consists of a central core of liposomes, surrounded by a layer of lipids, and an outer shell of liposomes. A green arrow points from the carrier to the eye. The eye is shown in two states: 'Normal Eye' and 'Eye with Glaucoma'. In the 'Normal Eye', the 'Exit of Intraocular Fluid' is shown. In the 'Eye with Glaucoma', the 'Exit of Intraocular Fluid' is blocked, leading to an increase in 'Intraocular Pressure'. The liposomal carrier is shown delivering 'Sustained siRNA' to the eye, which is used for 'Sustained siRNA delivery against SPARC'. A small inset image shows a red, fibrous structure, likely representing scar tissue formation after glaucoma filtration eye surgery. The text below the inset reads: 'Prevention of scar-tissue formation after glaucoma filtration eye surgery'. A caption below the inset states: 'Secreted protein, acidic, and rich in cysteine (SPARC) protein expression is associated with tissue scarring and fibrosis.'

**Sustained siRNA delivery against SPARC**

**Prevention of scar-tissue formation after glaucoma filtration eye surgery**


Secreted protein, acidic, and rich in cysteine (SPARC) protein expression is associated with tissue scarring and fibrosis.

ITACOMBI APTEL ONLINE CERTIFICATION COURSE 57

So let us see an example, so here you can see the normal eye and eye with the glaucoma okay, so we can liposomal carrier which can give drugs to this, again we can use the lipid carrier for preventing the scar tissue formation after the glaucoma filtration eye surgery. To prevent this formation of scar by using this sustained delivery against these SPARC. SPARC is secreted protein acidic and rich in cysteine okay. So we can reduce this SPARC protein expression is associated with tissue scarring and fibrosis.

(Refer Slide Time: 28:05)

## Multilayered nanoparticles as non-viral vectors for siRNA delivery



HA | Arginine | Dextrin or Anti-SPARC | Arginine | anti-SPARC\_siRNA | Arginine

• Multilayered self-assembly of siRNA nanocarriers are customizable, simple, solvent-free systems

• Layer decomposition in cytoplasm facilitate active release of siRNA for gene silencing

Small 2014, 10, No. 9, 1790-1796



MPH SIMM  
CERTIFICATION COURSE

58

So we can use multilayered nanoparticles as non viral vectors for siRNA delivery, so we can have these kind of multilayered nanoparticles and which will be carrying the SPARC, so this multilayered self assembly of a siRNA nanocarriers are customizable and these are simple, solvent, free systems and this layer will be decomposition in cytoplasm and it will facilitate active release of siRNA for gene silencing okay. So this will be useful for preventing the SPARC after the gal co surgery.

(Refer Slide Time: 28:42)


## Drug targeting to neoplastic diseases

So let us see drug targeting to neoplastic diseases, neoplastic means cancer okay.

(Refer Slide Time: 28:47)

## Targeted delivery to tumors

- Goal is to inject treatment far from tumor and have large accumulation in tumor and minimal accumulation in normal cells/organs.



IT KOOBER




MPH, ONLINE  
CERTIFICATION COURSE

60

So here the goal is to inject treatment far from tumor and have large accumulation in tumor and minimal accumulation in normal cells and organs, so this target deliver tumors, I have already discussed in one of my previous lecture in detail but so briefly we will see here how we can use this.

(Refer Slide Time: 29:02)



So here the most of the failure of the cancer treatment is the tumor penetration okay, so the tumor penetration is the key issue for the successful chemotherapy and most of the cases the drug cannot entered inside the location of tumor. So due to which what will happen? Tumor will re grow.

(Refer Slide Time: 29:27)


## Nanoparticle use in Cancer Treatments

- Because of their small size, nanoparticles can pass through interstitial spaces between necrotic and quiescent cells.
- Tumor cells typically have larger interstitial spaces than healthy cells
- Particles collect in center bringing therapeutics to kill the tumor from inside out.

So to overcome this we can use the nano particles, and these nano particles can pass through the interstitial space between necrotic and quiescent cells and these tumor cells typically have larger interstitial spaces than healthy cells and the particles collect in the center bringing therapeutics to kill the tumor from inside out.

(Refer Slide Time: 29:47)

## Nanoparticle use in cancer treatments




So you can see the nanoparticles can enter and only binding the tumor cells and can erratic the tumor cells.

(Refer Slide Time: 29:52)

## Nanoparticle targeting and accumulation

- To maximize their effectiveness, the microenvironment of the tumor must be quantified and vectors developed to specifically target the tumor.



And these nanoparticles to maximize their effectiveness the microenvironment of the tumor must be qualified and vectors developed to specifically target the tumor. So it can reach the inner part of the tumor then it can completely eradicate the tumor and it will prevent the re occurrence of tumor okay. In this lecture we have learn what nano pharmacology is and also we have learn what the various nano pharmacology targets are and how to target these drug to the particular organs okay. So I will end my lecture over here I thank you all for listening to this lecture and I will see you all in another interesting lecture.

**For Further Details Contact**  
**Coordinator, Educational Technology Cell**  
**Indian Institute of Technology Roorkee**  
**Roorkee – 247667**  
**E Mail: [etcell.iitrke@gmail.com](mailto:etcell.iitrke@gmail.com), [etcell@iitr.ernet.in](mailto:etcell@iitr.ernet.in)**  
**Website: [www.iitr.ac.in/centers/ETC](http://www.iitr.ac.in/centers/ETC), [www.nptel.ac.in](http://www.nptel.ac.in)**



**Production Team**

**Sarath Koovery  
Mohan Raj  
Jithin. K  
Pankaj saini  
Graphics**

**Binoy. V. P**

**Camera  
Arun. S  
Online Editing  
Arun. S  
Video Editing  
Arun. S**

**NPTEL Coordinator  
Prof. B. K. Gandhi**

**An Educational Technology cell  
IIT Roorkee Production  
© Copyright All Rights Reserved**